@article{wiegman2023evinacumab,
 abstract = {BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that severely elevated LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating a largely unmet need for aggressive LDLR-independent lipid-lowering therapies in young patients with HoFH. Here we present the first evaluation of the efficacy and safety of evinacumab, a novel LDLR-independent lipid-lowering therapy, in pediat...},
 author = {MD PhD Albert Wiegman and MD PhD Albert Wiegman and MD Susanne Greber-Platzer and PharmD Shazia Ali and MD M. Doortje Reijman and MD Eliot A Brinton and MD Min-Ji Charng and Pavithra Srinivasan and Priya Md and Mph Seth Baum Md and M. Brothers and M. Hartz and M. P. M. Md and MD Jeanne Mendell and M. PhD and P. Banerjee and Patty George and M. Hirshberg and MD Robert Pordy},
 doi = {10.1161/CIRCULATIONAHA.123.065529},
 journal = {Circulation},
 pages = {343 - 353},
 title = {Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia},
 volume = {149},
 year = {2023}
}